Evidence map›Paper›PMID 38669327›Full record

ArticleScience advances2024

The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: Insights from an in vitro model of collective detachment.

Hannah M Micek, Ning Yang, Mayuri Dutta, Lauren Rosenstock, Yicheng Ma, Caitlin Hielsberg, Molly McCord, Jacob Notbohm, Stephanie McGregor, Pamela K Kreeger

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Challenges and advances in drug resistance and tolerance in cancer.Journal of experimental & clinical cancer research : CR · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Journal of biomedical optics · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Piezo1-related physiological and pathological processes in glioblastoma.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hannah M MicekDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0001-7395-8250
Ning YangDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
Mayuri DuttaDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-2258-1358
Lauren RosenstockDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.
Yicheng MaDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-7392-3274
Caitlin HielsbergDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.
Molly McCordDepartment of Mechanical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0009-0007-9503-6274
Jacob NotbohmDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.
Stephanie McGregorDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.ORCID 0000-0002-7940-1143
Pamela K KreegerDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0001-8193-1007
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
The role of multi-cellular aggregates vs. individual tumor cells in metastasis of high-grade serous ovarian cancerR01CA240965 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KREEGER, PAMELA K · 2020 to 2025
$2.7M
Engineered ECM platforms to analyze progression in high grade serous ovarian cancerR01CA232517 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CAMPAGNOLA, PAUL J, KREEGER, PAMELA K · 2018 to 2022
$2.4M
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA232517NCI NIH HHS R01 CA240965
6 · The paper itself

Abstract

Slowing peritoneal spread in high-grade serous ovarian cancer (HGSOC) would improve patient prognosis and quality of life. HGSOC spreads when single cells and spheroids detach, float through the peritoneal fluid and take over new sites, with spheroids thought to be more aggressive than single cells. Using our in vitro model of spheroid collective detachment, we determine that increased substrate stiffness led to the detachment of more spheroids. We identified a mechanism where Piezo1 activity increased MMP-1/MMP-10, decreased collagen I and fibronectin, and increased spheroid detachment. Piezo1 expression was confirmed in omental masses from patients with stage III/IV HGSOC. Using OV90 and CRISPR-modified

Indexed as

Ion ChannelsMechanotransduction, CellularOvarian NeoplasmsSpheroids, CellularAnimalsCell Line, TumorCystadenocarcinoma, SerousFemaleHumansMiceNeoplasm GradingIon ChannelsPIEZO1 protein, humanPiezo1 protein, mouse

Identifiers

PMID38669327
PMCPMC11051664
OpenAlexW4395661637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.